Our Pipeline

Our integrated approach is uniquely positioned to disrupt immunotherapies for cancer. Our initial areas of development will focus on the parallel advancement of Umoja’s core platforms with the goal of bringing together these technologies as a scalable, next-generation process for solid tumor and hematologic malignancies immunotherapy.


Our lead candidate programs are:

VivoVec UB-VV100 engineering cells with RACR-CD19 CAR

For hematological cancers

TumorTag UB-TT170 with Ex Vivo TagCAR T cells

In pediatric osteosarcoma

Umoja is driven by a bold and unified vision to transform cancer treatment and improve quality of life. We are a diverse group of drug development experts, scientists and researchers that are skilled, passionate, persistent, and committed to finding a way to break through the current challenges seen in immuno-oncology today.